Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rubeen K Israni

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Seminars in Dialysis|September 15, 2006
Use of antiepileptic drugs in patients with kidney diseaseRubeen K Israni, Nishaminy Kasbekar, Kevin Haynes, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 11, 2009
Physician characteristics and knowledge of CKD managementRubeen K Israni, Judy A Shea, Marshall M Joffe, et al.
Journal of the American Society of Nephrology : JASN|November 16, 2007
Hemoglobin variability and mortality in ESRDWei Yang, Rubeen K Israni, Steven M Brunelli, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 14, 2008
History-adjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patientsSteven M Brunelli, Marshall M Joffe, Rubeen K Israni, et al.
Kidney International|February 12, 2004
Willingness of dialysis patients to participate in a randomized controlled trial of daily dialysisAjay K Israni, Scott D Halpern, Christopher McFadden, et al.
Lancet (London, England)|September 28, 2025
Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 studyDavid Kavanagh, Andrew S Bomback, Marina Vivarelli, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Seminars in Dialysis|September 15, 2006
Use of antiepileptic drugs in patients with kidney diseaseRubeen K Israni, Nishaminy Kasbekar, Kevin Haynes, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 11, 2009
Physician characteristics and knowledge of CKD managementRubeen K Israni, Judy A Shea, Marshall M Joffe, et al.
Journal of the American Society of Nephrology : JASN|November 16, 2007
Hemoglobin variability and mortality in ESRDWei Yang, Rubeen K Israni, Steven M Brunelli, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 14, 2008
History-adjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patientsSteven M Brunelli, Marshall M Joffe, Rubeen K Israni, et al.
Kidney International|February 12, 2004
Willingness of dialysis patients to participate in a randomized controlled trial of daily dialysisAjay K Israni, Scott D Halpern, Christopher McFadden, et al.
Lancet (London, England)|September 28, 2025
Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 studyDavid Kavanagh, Andrew S Bomback, Marina Vivarelli, et al.
Pageof 1